• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis
【24h】

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis

机译：皮下干扰素-β-1a在首次脱髓鞘事件和早期多发性硬化症患者中的疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS. Evidence suggests that MS should be treated as early as possible in order to maximize the benefit of treatment.Areas covered: This review details current understanding about the treatment of relapsing-remitting MS (RRMS). The pharmacological and clinical data on the use of subcutaneous (s.c.) interferon β-1a (IFN-β-1a) as a therapeutic option for RRMS are covered, with a focus on the importance of treating patients with MS as early as possible in the course of the disease, in order to delay permanent axonal damage that is responsible for the signs and symptoms of disease progression.Expert opinion: There is a wealth of data on the treatment of RRMS with s.c. IFN-β-1a indicating that patients treated during the early inflammatory stages of the disease have significantly improved short-term outcomes compared with patients who commence treatment late. It remains to be determined whether the short-term effects of early treatment will translate into long-lasting benefits, although it is hoped that ongoing research will help to answer this question.
机译：简介：多发性硬化症（MS）是中枢神经系统的一种炎症性脱髓鞘疾病。有证据表明，应尽早治疗MS，以使治疗获益最大化。覆盖范围：本篇综述详细介绍了目前对复发缓解型MS（RRMS）治疗的理解。涵盖了使用皮下（sc）干扰素β-1a（IFN-β-1a）作为RRMS的治疗选择的药理学和临床数据，重点在于尽早治疗MS患者的重要性。在病程中，为了延迟造成疾病进展迹象和症状的永久性轴突损伤。专家意见：关于使用SC治疗RRMS有大量数据IFN-β-1a指示与早期开始治疗的患者相比，在疾病早期炎症阶段接受治疗的患者的短期结局得到了显着改善。尽管希望正在进行的研究将有助于回答这个问题，但早期治疗的短期效果是否会转化为长期效果仍有待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号